What Patients Should Know Right Now The FDAs formal action takes effect April 23, 2026, with the PCAC review of these substances scheduled for July 23-24, 2026
Same-day booking available
It can be, especially for those who respond well to GLP-1 medications and want a daily alternative to injections
The complexity exceeds what most independent researchers can safely manage
The mechanism is intriguing: by mimicking the GLP-1 hormone naturally produced in the body, semaglutide slows down gastric emptying and influences the central nervous system to reduce hunger and increase feelings of fullness
One key misunderstanding is that this is a disease of willpower, when in fact there is underlying biology that prevents people from losing weight and keeping it off. Novo Nordisk also provides funding for medical education on obesity, including one session for nurses called Obesity: The Elephant in the Room. Novo Nordisk was recently suspended for two years from a pharmaceutical lobbying group in the U.K